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Value of continuous leakage monitoring with radio-
active Iodine-131 labeled human serum albumin





The aim of this study was to analyze the value of continuous leakage monitoring with
radioactive Iodine-131 labeled human serum albumin (RISA) in patients treated with
hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF)
and melphalan. Forty-eight patients with melanoma (n = 14) or soft tissue sarcoma
(n = 34) of an extremity underwent 51 perfusions. Perfusion was performed at the
iliac level in 22 cases, at the popliteal level in 16 cases, at the femoral level in 7
cases and in 6 cases at the axillary level. Leakage rates, perfusion circuit and systemic
levels of TNF, interleukin-6, C-reactive protein (CRP) were determined, as were
systemic hematological and metabolic profiles and tumor response. The mean
isotopically measured leakage was 2.9 % (95% confidence interval 2.0 – 3.8%, range
0-15.5%). Systemic leakage was ≤2% in 28 perfusions (55%) and >2% in 23
perfusions (45%). The correlation between the maximal monitored leakage and
maximal systemic TNF levels was 0.7114 (p < 0.0001). The area under the curve
(AUC) for TNF in the perfusion circuit, indicating the exposure of the perfused limb
to TNF, was 18.7% lower in the >2% leakage group (p=0.0457). No significant
differences in tumor response were found between groups. AUC for systemic TNF,
indicating the exposure of the patient to TNF, was 18.1 times higher in the >2%
leakage group (p<0.0001) resulting in a significant decrease in leucocyte and platelet
count, hyperbilirubinemia, hypocholesterolemia and proteinemia. No beneficial effect
of the systemically leaked TNF and melphalan was seen on the occurrence of distant
metastasis during follow-up. There was a significant difference between perfusions
performed at the iliac and femoral levels compared with leakage values at the popliteal
level, p < 0.0001 and 0.0159 respectively. A good correlation between RISA leakage
measurement and TNF exposure during and after HILP with TNF and melphalan
was demonstrated. RISA leakage measurement serves as a good guide for the
effectiveness of isolation during perfusion. If leakage exceeds the 2% limit during
perfusion, less exposure of the tumor bearing limb to TNF,  increased exposure of the
patient systemic circulation to TNF, and more systemic side effects can be expected.
Introduction
Creech and Krementz developed isolated limb perfusion with chemotherapy for the
treatment of extremity melanoma in humans in 1958.1 Stehlin et al modified the
technique in 1969 to include hyperthermia.2 Since then, hyperthermic isolated limb
perfusion (HILP) with different chemotherapeutic agents has been used by several
institutes worldwide for the treatment of advanced extremity melanoma and soft
tissue sarcoma. Recently, an international study comparing local excision and adjuvant
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HILP with melphalan with wide excision only revealed a trend for a longer disease-
free interval after HILP with melphalan but no benefit from HILP in terms of time to
distant metastasis or survival.3 With the conclusion that prophylactic HILP with
melphalan could not be recommended as an adjunct to standard surgery in high-risk
primary limb melanoma, the indication for HILP is currently restricted to advanced
melanoma and primarily irresectable soft tissue sarcoma. For these indications the
addition of tumor necrosis factor alpha (TNF) to melphalan seems promising.4,5
With the introduction of TNF, monitoring of leakage of the isolated circuit into the
systemic circulation has been mandatory since TNF levels in the perfusion circuit
are approximately 10 times the maximum tolerated systemic levels.6 If significant
leakage occurs during HILP, the resultant TNF induced systemic inflammatory
response syndrome (SIRS) could be fatal.7 Different methods for measurement of
leakage are used. In the early days, Stehlin et al determined the amount of radioactive
Iodine-131 labeled human serum albumin (RISA) through the use of blood samples
from the systemic circulation, and calculated the leakage factor (LF).8 Although
determination of blood samples takes time and is discontinuous, it is frequently used
by other groups.9,10 To overcome these disadvantages, Stehlin and associates were
the first to describe a method of continuous external leakage monitoring with RISA.11
Because of safety regulations, nuclear medicine techniques are not always allowed
in the operation zoom. Another method, the measurement of Evans blue concentration
in plasma by means of a spectral photometer, overcomes this problem.12 Two other
groups introduced the use of handheld gamma detectors for leakage measurements;
however, a great dependency was observed on the distance and angle from the source
with this system.13,14
Since 1991, patients with advanced melanoma or soft tissue sarcoma of the limbs,
have been treated at the Groningen University Hospital by HILP with TNF, melphalan
with or without interferon gamma (IFN) as perfusion agents, followed by delayed
surgical excision. The aim of this study was to analyze the value of continuous leakage
monitoring with RISA in patients treated with TNF perfusion with respect to systemic
levels of TNF, interleukin (IL)-6, C-reactive protein (CRP) as well as hematological
and metabolic profiles and tumor response.
Patients and methods
Forty-eight patients with melanoma (n = 14) or soft tissue sarcoma (n = 34) of the
extremity underwent 51 perfusions with a combination of TNF and melphalan, with
or without IFN. Twenty-one males and 27 females, with a median age of 54 years
(range 18-80 years) were treated. Perfusion was performed at the iliac level in 22
cases (43%), at the popliteal level in 16 cases (31%), at the femoral level in 7 cases
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(14%), and in 6 cases (12%) at the axillary level. All patients were treated after
informed consent was obtained according to institutional guidelines.
Perfusion Technique
The perfusion technique employed at the Groningen University Hospital is based on
the technique developed by Creech et al.1 and has been described in detail previously.15
Briefly, after ligation of all collateral vessels and heparinization of the patient with
3.3 mg heparin/kg bodyweight (Thromboliquine, Organon BV, Oss, the Netherlands),
the axillary, iliac (internal iliac artery is temporarily closed), femoral, or popliteal
vessels were cannulated and connected to an extracorporal circuit. The perfused limb
was wrapped in a thermal blanket to reduce heat loss. To prevent collateral circulation
in subcutaneous tissue and muscle, an occluding rubber bandage was twisted around
the root of the extremity and fixed around a pin inserted into the head of the humerus
(axillary perfusion) or iliac crest (iliac perfusion). An inflating tourniquet was used
in femoral or popliteal perfusions. Perfusion was performed during 90 min under
mild hyperthermia (39-40°C) and physiologically optimal conditions.16 At the start
of perfusion, 3 mg (upper extremity) or 4 mg (lower extremity) TNF (Boehringer,
Ingelheim, Germany) was injected as a bolus into the arterial line. Eighteen patients
also received a dose of 0.2 mg INF (Boehringer, Ingelheim, Germany) subcutaneously
1 and 2 days before perfusion, followed by 0.2 mg INF injected into the arterial line
at the start of perfusion. Melphalan (L-phenylalanine mustard, Glaxo-Wellcome,
London, England) was administered 30 min later, as 10 mg/L extremity volume (leg)
or 13 mg/L extremity volume (arm).17 The volume of the limb was determined before
surgery  by immersion.
All perfusions were performed with a bubble oxygenator roller pump and heat





of 350 ml 5% dextran 40 in glucose 5% (Isodex, Pharmacia AB, Uppsala, Sweden),
500 ml blood (250 ml red blood cells, 250 ml plasma), 30 ml of 8.4% NaHCO
3
, 0.5
ml 5000 IU/ml heparin. The perfusions were flow regulated on the basis of the arterial
and venous pressure measured at one end of the double lumen catheter used. After 90
min of perfusion, the limb was flushed with 2 L dextran 40 in glucose 5% (Isodex)
and 500 ml blood (250 ml red blood cells, 250 ml plasma), catheters were removed,
the circulation restored and the heparin antagonized with protamine chloride (Hoffman
La Roche, Mijdrecht, the Netherlands). A lateral fasciotomy of the anterior
compartment of the lower leg or arm was performed to prevent a compartment
syndrome.18
111
Leakage during isolated limb perfusion with TNF
Leakage Measurement
Any leakage into the systemic circulation was continuously monitored with radioactive
tracers. A small calibration dose of RISA (0.5 MBq) and a dose of radioactive
Technetium-99m labeled human serum albumin (RTcSA; 10 MBq) were administered
into the systemic circulation, after surgical isolation of the extremity was
accomplished. The thyroid was saturated 1 day before the operation by oral
administration of iodine (15 drops of Lugol solution twice daily). A 10 times higher
dose of RISA (5 MBq) was injected into the perfusion circuit when perfusion was
stable. The 364-keV gamma rays emerging from the RISA and the 140-keV gamma
rays emerging from the RTcSA are measured with a NaI detector, which was placed
in a flat field lead lined collimator that was mounted on an articulating mobile stand.
This stand permits easy positioning of the detector, after it is covered with a sterile
bag, above the heart of the patient. Careful attention is paid to ensure that the field of
view of the detector did not cover parts of the HILP circuit. The detector signals
generated by the photomultiplier tube were directed to an amplifier and then to a
single-channel analyzer, allowing online data processing by a personal computer.
The count rate of the 0.5-MBq RISA determined a baseline count level, corrected for
room background. The 10-MBq RTcSA served to check the volume dilution caused
by to fluid infusions or displacement of the NaI detector during the registration period.
Leakage from the perfused limb to the systemic circulation resulted in an increase of
the baseline count level. This increase, corrected for the blood volume ratio and the
radioactivity ratio in both compartments, was a direct measure for the percentage of
leakage and was continuously registered during the whole procedure. Stehlin was
the first to describe the LF based on the following equation:
where cpm
systemic
 is the systemic count rate observed during perfusion, cpm
baseline
 is
the systemic count rate at the beginning of perfusion, D
systemic
 is the dose injected into
the patient’s systemic circulation, and D
perfusion
 is the dose injected into the perfusion
circuit V
total
 is the total blood volume (perfusion circuit + patient’s systemic
circulation), V
systemic
 is the blood volume of the patient’s systemic circulation.11
Blood sampling procedure and assays
A baseline blood sample from the patients systemic circulation was taken from an
indwelling radial artery cannula before the start of the operation, and at 5, 30, 60,
LF = 
(cpmsystemic - cpmbaseline)
  < >  
Dsystemic
  < >  
Vtotal
  < >  100%
                  cpmbaseline                        Dperfusion        Vsystemic
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and 89 min after the start of perfusion. Samples from the perfusion circuit were also
taken at the same time intervals. After restoration of the circulation in the perfused
limb, systemic samples were taken at 1, 5, 10, 30 and 60 min after removal of the
arterial clamps, hourly thereafter for at least 8 hours and finally the next morning.
Venous blood samples to study the hematological and metabolic profiles of urea
nitrogen, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase,
alanine aminotransferase, gammaglutamyltranspeptidase, protein, cholesterol, lactic
dehydrogenase (LDH) with its iso-enzymes, creatine phosphokinase and myoglobin
were taken a day before perfusion, at the day of perfusion, and every day after
perfusion until day 7. A final blood sample was taken one month after perfusion.
Blood samples (3 ml) were collected in EDTA vacutainer tubes, and kept on melting
ice during transport to a centrifuge. Samples were centrifuged for 10 min at 3000
rpm at 0°C and the separated plasma kept at –80°C until analysis.
TNF levels were determined by specific immunoradiometric assay (Medgenix
Diagnostics, Soesterberg, the Netherlands). Samples were processed according to
the guidelines of the manufacturer. IL-6 and CRP levels were measured by in-house
sandwich ELISA’s as described previously19, by using commercial reagents for IL-6
(CLB, Amsterdam, the Netherlands; detection limit 10 ng/L) and for CRP (DAKO,
Glostrup, Denmark; normal level <2.3 mg/L).
Assessment of tumor response
Responses were assessed by standardized World Health Organization criteria.20
Complete response (CR) was defined as the disappearance of all measurable disease
in the limb for longer than 4 weeks, partial response (PR) as regression of the tumor
size by  >50% for longer than 4 weeks, and no change (NC) as regression of <50% of
the tumor in the limb or progression of <25% for longer than 4 weeks. To analyze
whether or not a high systemic leakage was of influence in the occurrence of distant
metastasis subanalyses of this parameter in a group of patients with grade II and III
soft tissue sarcomas was performed.
Statistical analysis
Values are expressed as mean ± SEM. Comparison between mean values of different
groups was performed with the unpaired or in case of measuring the same variable in
the same patient at different time points, with the paired Student’s t-test. Areas under
the curve (AUC) were determined by the trapezoid rule. Survival curves were
calculated according to the Kaplan Meier method and log rank test.21 Values of
p ≤ .05 were considered to be statistically significant. Graph Pad Prismâ version 2.0
for Windows (GraphPad, San Diego, CA) statistical software was used.
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Results
Systemic leakage
For the 51 perfusions, the mean isotopically measured leakage was 2.9 % (95%
confidence interval, 2.0 – 3.8%, range 0-15.5%). After 60 minutes of perfusion in
the patient with the highest leakage (15.5%), it was noted that the rubber bandage
twisted around the root of the extremity was ruptured. Since this was the cause of the
high leakage and perfusion was not completed, the data from this patient are excluded
from the remainder of the analyses. Systemic leakage was ≤ 2% in 28 perfusions
(55%) and >2% in 23 perfusions (45%). In the latter group, 11 perfusions (22%) led
to systemic leakage of >5%. In addition, analysis of different parameters between
the group of patients with ≤ 2% leakage and the group of patients with >2% leakage,
was made. Figure 1 shows the measured leakage at different perfusion levels. There
was a significant difference between perfusions performed at the iliac and femoral
levels compared with leakage values at the popliteal level, (p < 0.0001 and 0.0159
respectively). There was no leakage encountered in patients with axillary perfusions.
Fig. 1 Scatter diagram of leakage at dif-
ferent perfusion levels, the uninterrupted
line represents mean values. A significant
difference was observed between perfu-
sions performed at the iliac and femoral
levels compared with leakage values at
the popliteal level, (p < 0.0001 and
0.0159 respectively)
Perfusion circuit levels
At 5 minutes, mean TNF levels in the perfusion circuit were 6798 ± 528 ng/ml
(Fig. 2). During perfusion, a significant drop in TNF levels in the perfusion circuit
occurred with a significant lower concentration of TNF in the perfused limb in patients
with >2% leakage at 30 (p = 0.0201), 60 (p = 0.0337) and 89 minutes (p = 0.002).
The calculated mean AUC, indicating the exposure of the perfused limb to TNF, was
18.7% less in the >2% leakage group (p=0.0457). IL-6 levels in the perfusate, as one
of the most important proinflammatory cytokines, progressively increased from 30
minutes until the end of the perfusion, reaching 4.2 ± 1.1 ng/ml in the ≤2% leakage
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Fig. 2 Tumor necresis factor (TNF)
levels in the perfusion circuit (mean ±
SEM). A significant decrease in TNF
levels occurred with significant lower
concentration of TNF in the perfused
limb in patients with >2% leakage at
30 (p = 0.0201), 60 (p = 0.0337) and
89 minutes (p = 0.002). Mean area un-
der the curve, indicating the exposure
of the perfused limb to TNF, was 18.7%
less in the >2% leakage group
group and 11.7 ± 3.5 ng/ml in the >2% leakage group (p=0.0455). CRP levels in the
perfusion circuit remained at the detection level, and no significant differences were
observed between the leakage groups.
Systemic levels
Systemic TNF levels in patients with >2% leakage were already significantly higher
at 5 min after TNF injection compared with the group of patients with ≤2% leakage.
Peak systemic TNF values of 116.5 ± 28.9 ng/ml were reached in the >2% leakage
group at the end of perfusion, compared with 11.8 ± 3.4 ng/ml in the ≤2% leakage
group (p < 0.0001) (Fig. 3). The calculated mean systemic AUC, indicating the
exposure of the patient to TNF, was 18.1 times higher in the >2% leakage group
(p<0.0001). Ten minutes after release of the tourniquet we observed a significant
systemic peak level of TNF in the ≤2% group possibly caused by the TNF still present
in the perfused limb after the washout procedure (p=0.026). To calculate the correlation
between maximum systemic TNF levels and the maximum monitored leakage using
RISA measured during perfusion, Pearson’s correlation (two-tailed) was used. Figure
4 illustrates the observed correlation with r = 0.7114 and p < 0.0001. A strong
correlation was also found between the maximal observed leakage and maximum
IL-6 concentration measured in the postoperative period (r = 0.7737, P<0.0001).
IL-6 levels appeared in the systemic circulation 30 minutes after the start of the
perfusion and maximal levels were reached 2 hours after HILP (19.5 ± 5.8 ng/ml
≤2% leakage versus 77.7 ± 20.8 ng/ml >2% leakage; p=0.0089). The AUC of IL-6
was 4.7 times higher in the >2%leakage group compared with ≤2% leakage group
(p<0.0243).
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CRP started to increase 6 hours after HILP and reached its maximal value 2 days
after perfusion (185.8 ± 25.5 mg/L ≤2% leakage versus 226.7 ± 32.7 mg/L, >2%
leakage; not significant). The AUC of CRP between both groups however was not
significantly different.
Hematological and metabolic parameters
Leukocyte counts increased from 7.7 ± 0.3x109/L to 13.0 ± 0.6x109/L one day after
perfusion. Five, 6, and 7 days after perfusion a significant difference between the
two leakage groups was observed (Fig. 5). Platelet counts decreased from 303.6 ±
13.4x109/L before perfusion to 124.3 ± 10.7x109/L 4 days after perfusion.
Fig. 3 Tumor necrosis factor (TNF) lev-
els in the systemic circulation of the pa-
tient (mean ± SEM). A significant dif-
ference was found between the >2%
leakage group and the ≤2% leakage
group is starting 5 min after TNF injec-
tion until the second postoperative day
(p<0.05). The mean systemic area un-
der the curve, indicating the exposure
of the patient to TNF, was 18-times
higher in the >2% leakage group
Fig. 4 Pearson’s correlation (two-
tailed) between maximal systemic TNF
levels measured during perfusion and
maximal monitored leakage using
RISA (r = 0.7114 and P<0.0001)
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The low platelet levels persisted longer in the >2% leakage group. Kidney function
was well preserved in all patients, although urea nitrogen and creatinine levels in the
>2% leakage group were significantly higher during the first 5 days after perfusion;
these levels however remained within normal limits. Liver function tests showed an
increase in bilirubin values from 10.5 ± 0.9 µmol/L to 44.8 ± 11.3 µmol/L, 4 days
after perfusion in the >2% leakage group, with significant differences compared with
the ≤2% leakage group (Fig. 6). Figure 6 illustrates the decrease in protein levels and
cholesterol levels after perfusion, with significant differences between both leakage
groups. Alkaline phosphatase increased from 86.1 ± 6.5 U/L to 159.4 ± 32.8 U/L,
aspartate aminotransferase increased from 22.8 ± 1.5 U/L to a maximum of 62.1 ±
13.4 U/L on the fifth day after perfusion, alanine aminotransferase increased from
21.9 ± 2.6 U/L to a maximum of 80.3 ± 11.6 U/L on the sixth day after perfusion, and
gammaglutamyltransferase increased from 37.7 ± 8.7 U/L to a maximum of 120.1 ±
18.6 U/L on the sixth day after perfusion. LDH increased from 224.8 ± 9.0 U/L to a
maximum of 417.3 ± 19.1 U/L on the second day after perfusion. LDH iso-enzymes
1 and 2 showed a decrease, whereas LDH iso-enzymes 4 and 5 increased one day
after perfusion. LDH iso-enzyme 3 remained at the same level. Creatine phospho-
kinase levels increased from 28.3 ± 2.4 U/L to a maximum of 496.4 ± 197.6 U/L on
Fig. 5 White blood cell count (WBC)
and platelets (PLT) levels from before
perfusion to 30 days after perfusion
(mean ± SEM). * indicates a significant
difference between both leakage groups
(p < 0.05)
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the second day after perfusion. Myoglobin levels increased from 30.2 ± 2.4 µg/L to
a maximum of 422.8 ± 99.7 µg/L one day after perfusion. None of these variables
showed a significant difference between both leakage groups.
Tumor Response
In the ≤2% leakage group, 14 patients showed a CR and the same number of patients
a PR. In the >2% leakage group, 11 patients showed a CR, 10 patients a PR and 2
patients had NC. No significant differences in response to TNF HILP were found
between the groups. No significant difference was observed in the occurrence of
distant metastasis or survival in the subanalyses of a group of patients with grade II
or III soft tissue sarcoma and >2% leakage (Fig. 7).
Fig. 6 Bilirubin, protein and cholesterol
levels from before perfusion to 30 days
after perfusion (mean ± SEM). * indicates
a significant difference between both leak-




The purpose of continuous leakage monitoring with RISA during HILP is to indicate
the amount of chemotherapeutic agent that is leaking from the perfusion circuit into
the patient’s systemic circulation. When leakage occurs, measures to reduce leakage
should be available. During perfusion there is a dynamic balance between two pressure
compartments: the patients systemic vasculature and the isolated circuit. The pressure
of the former compartment can be influenced by adjusting the systemic blood pressure,
whereas that of the latter can be affected by alterations in the extracorporeal flow
rate. Thus, to decrease leakage, the anesthesiologist can increase the patient’s blood
pressure or the surgeon can reduce the flow rate in the heart-lung machine. Different
methods for measurement of leakage have been used. The previously described method
with RISA is the most frequently used; however, a MEDLINE search to find any
articles calculating the correlation between systemic melphalan levels and leakage
in case of HILP with melphalan only, produced no results. The first report on TNF
levels after HILP with TNF, from Gérain et al. in 1992, demonstrated no significant
correlation between leakage and cytokine levels at any time, raising questions about
the value of the leakage measurement procedure.6
The aim of this study was to investigate whether or not the RISA leakage
measurements during HILP with TNF used in the Groningen University Hospital are
accurate in predicting systemic TNF levels. We observed a good correlation between
maximal systemic TNF levels and the maximum monitored leakage (r = 0.7114;
p < 0.0001). We were surprised to find that the correlation between maximal leakage
and maximal IL-6 concentration measured in the postoperative period was higher
than the correlation between maximal leakage and maximal TNF levels (r = 0.7737
versus r = 0.7114). IL-6 levels occurred in response to TNF, with a high correlation
between maximal levels of both cytokines (r = 8097). Stam et al. also found a strict
correlation between the degree of leakage estimated by isotope monitoring and the
Fig. 7 Absence of distant metastasis in
patients with grade II or III soft tissue sar-
coma. No significant difference was found
between the >2% leakage group and the
≤2% leakage group
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measured maximal systemic TNF levels in the same treatment setting (r = 0.7886,
p=0.0067; calculation based on their data).22 They also found a sharper relation
between systemic IL-6 curves and duration of exposure to high TNF levels in patients
with high leakage compared with a group of patients with no leakage. A significant
difference in leakage was found between the iliac/femoral perfusion levels and
popliteal perfusion level. This corresponds with the study of Klaase et al., who assessed
six variables for their influence on systemic leakage. The level of isolation and the
diameter of the venous cannula emerged as significant factors.23 In our study we
could not find a significant role for the diameter of the venous cannula (data not
shown). The importance of the perfusion level could be partly explained by the
different type of isolation technique used, namely, a rubber band tourniquet at the
iliacal level versus a inflatable pressure regulated band at the popliteal level.
In the analysis of our data, we distinguished two leakage groups, with a cutoff point
at 2%. Two percent represents approximately the measurement fault of the RISA
procedure. TNF levels in the perfusion circuit were about 7000 ng/ml, approximately
50-times higher than peak systemic levels. A significantly lower concentration of
TNF in the perfused limb in patients with >2% leakage was demonstrated resulting
in a decreased AUC, indicating an 18.7% lower exposure of the perfused limb to
TNF in the >2% leakage group. This decrease in TNF exposure, however, did not
result in a significant reduction of tumor response between the groups. This result
supports the initiation of TNF dose reduction studies. Thom et al. observed the same
decreased TNF perfusion circuit levels in patients with ≥1% leakage.24 The Rotterdam
perfusion group did not demonstrate a significant difference in perfusion circuit TNF
levels between a high and low-leakage group, possibly because of a limited number
of samples available.22
TNF levels in the systemic circulation of the patients were approximetely 100 ng/ml
in the >2% leakage group at the end of perfusion, compared with 10 ng/ml in the
≤2% leakage group. In patients with ≤2% leakage, systemic TNF exposure was 18.1
times less as calculated by the AUC. On the basis of the hypothesis that micro
metastatic disease is attacked by the leaked TNF and melphalan, a higher systemical
exposure of TNF could have its effect on the occurence of distant metastasis during
follow-up. However, subanalysis of the occurence of distant metastasis or survival
in a group of patients with grade II or III soft tissue sarcomas did not reveal this
phenomenon. IL-6, as one of the most important proinflammatory cytokines, appeared
in the systemic circulation 30 minutes after the start of the perfusion with maximum
levels reached 2 hours after HILP. CRP levels started to increase 6 hours after HILP
and reached its maximum 2 days after perfusion. A three wave pattern was seen; the
first wave caused by the systemically leaked TNF that generated a second wave of
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IL-6 some hours after perfusion, followed by a third wave of CRP that lasts for
several days.
TNF leakage was associated with a decrease in leucocyte and platelet count, with
significantly lower values in the >2% leakage group. Representing cytolytic liver
toxicity, a significantly hyperbilirubinemia, hypocholesterolemia and proteinemia
was observed in the >2% leakage group. A increase in the activity of the fraction of
LDH iso-enzymes 4 and 5 after perfusion was partly related to hepatotoxicity and
partly to muscle damage. No significant difference between both leakage groups
was found for creatine phosphokinase levels or myoglobin levels although both
parameters showed a significant rise after HILP. The same results were obtained by
Sorkin et al. who diminished TNF leakage after flow rate reduction during TNF
HILP.25 Analysis of our own flow data in relation to systemic leakage revealed a
weak negative correlation of r = -0.2910 with p = 0.0448 with a mean flow of 455 ±
172 ml/min in our perfusions.
Like others, we also found a significant systemic TNF peak in patients with low
leakage after restoration of the circulation of the perfused limb.22,26 Despite a washout
procedure with 2 L of Isodex, TNF in the limb reaches the systemic circulation. A
corresponding rise in RISA was also observed.27 Therefore, today a more extensive
washout with 6 L and massage of the perfused limb is recommended in TNF perfusions
to reduce TNF release.
In a previous study we described the clinical features of HILP with TNF characterized
by a short- lived sepsis-like syndrome.28 This best called SIRS, was seen in all patients
and accompanied by fever, increase in cardiac output, a decrease in systemic vascular
resistance, and the need for fluid resuscitation and inotropes. Perfusion with melphalan
as the sole perfusion agent did not trigger these effects. Detailed analysis showed
positive correlations between maximum TNF concentrations and systemic vascular
resistance and cardiac index. The National Cancer Institute perfusion group
demonstrated the relation between the vascular response with the need for vasopressor
support and systemic TNF levels in patients with TNF leakage as well.24 Lejeune
also demonstrated severe toxicity in patients with leaks of >5%.4,6 Vrouwenraets et
al. reported an absence of severe systemic toxicity of TNF in patients without systemic
leakage.26 Stam et al. observed only a mild postoperative toxicity in the event of
significant leakage during perfusion.22 This was easily managed on the intensive
care unit with fluid substitution and, in some cases, vasopressors. On the basis of
their data, they rightly plead for renewed study of the potential use of TNF
systemically. Currently, SIRS is only seldom seen since the majority of the institutions
performing HILP with TNF and melphalan are experienced and are using a more
extensive washout procedure. One could ask oneself if leakage measurements during
121
Leakage during isolated limb perfusion with TNF
HILP are still worthwhile when side effects of TNF leakage are so easily dealt with.
In this study we demonstrated a good correlation between RISA leakage measurement
and TNF exposure during and after HILP with TNF and melphalan. RISA leakage
measurement serves as a good guide for the effectiveness of isolation during perfusion.
If leakage exceeds the 2% limit during perfusion, less exposure of the tumor bearing
limb to TNF, an increased exposure of the patient’s systemic circulation to TNF, and
more systemic side effects can be expected. Because leakage >2% did not influence
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